DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts Dana Farber Cancer Institute, Boston, Massachusetts Brigham and Women's Hospital, Boston, Massachusetts Age range
18 Years and older
Last updated January 2026